Yüklüyor......
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
BACKGROUND: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median progression-free survival of 12–18 months. There...
Kaydedildi:
| Yayımlandı: | J Transl Med |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5024442/ https://ncbi.nlm.nih.gov/pubmed/27634150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-1027-1 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|